Dosimetric model for intraperitoneal targeted liposomal radioimmunotherapy of ovarian cancer micrometastases.
A simple model has been developed to investigate the dosimetry of micrometastases in the peritoneal cavity during intraperitoneal targeted liposomal radioimmunotherapy. The model is applied to free-floating tumours with radii between 0.005 cm and 0.1 cm. Tumour dose is assumed to come from two sources: free liposomes in solution in the peritoneal cavity and liposomes bound to the surface of the micrometastases. It is assumed that liposomes do not penetrate beyond the surface of the tumours and that the total amount of surface antigen does not change over the course of treatment. Integrated tumour doses are expressed as a function of biological parameters that describe the rates at which liposomes bind to and unbind from the tumour surface, the rate at which liposomes escape from the peritoneal cavity and the tumour surface antigen density. Integrated doses are translated into time-dependent tumour control probabilities (TCPs). The results of the work are illustrated in the context of a therapy in which liposomes labelled with Re-188 are targeted at ovarian cancer cells that express the surface antigen CA-125. The time required to produce a TCP of 95% is used to investigate the importance of the various parameters. The relative contributions of surface-bound radioactivity and unbound radioactivity are used to assess the conditions required for a targeted approach to provide an improvement over a non-targeted approach during intraperitoneal radiation therapy. Using Re-188 as the radionuclide, the model suggests that, for microscopic tumours, the relative importance of the surface-bound radioactivity increases with tumour size. This is evidenced by the requirement for larger antigen densities on smaller tumours to affect an improvement in the time required to produce a TCP of 95%. This is because for the smallest tumours considered, the unbound radioactivity is often capable of exerting a tumouricidal effect before the targeting agent has time to accumulate significantly on the tumour surface.
Syme
A M
AM
Department of Physics, University of Alberta. 412 Avadh Bhatia Physics Laboratory, Edmonton, Alberta, Canada T6G 2J1. asyme@phys.ualberta.ca
McQuarrie
S A
SA
Middleton
J W
JW
Fallone
B G
BG
D055592:Biophysical Phenomena; D001703:Biophysics; D018394:CA-125 Antigen / Q000378:metabolism; D003198:Computer Simulation; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D008081:Liposomes; D008954:Models, Biological; D010051:Ovarian Neoplasms / Q000276:immunology / Q000532:radiotherapy*; D010534:Peritoneal Neoplasms / Q000276:immunology / Q000532:radiotherapy* / Q000556:secondary*; D016499:Radioimmunotherapy / Q000379:methods* / Q000706:statistics & numerical data; D011868:Radioisotopes / Q000627:therapeutic use; D011880:Radiotherapy Planning, Computer-Assisted / Q000706:statistics & numerical data*; D018714:Radiotherapy, Adjuvant; D012211:Rhenium / Q000627:therapeutic use
D018394:CA-125 Antigen; D008081:Liposomes; D011868:Radioisotopes; D012211:Rhenium